In the claims:

1-112. **(Cancelled)**

113. **(Currently amended)** A method for inducing a therapeutic host immune response against a multi-epitopic *in vivo* antigen that does not elicit an effective host immune response, the method comprising:

contacting a multi-epitopic antigen present in a host's serum with a composition comprising a binding agent that specifically binds to a first epitope on the antigen, the binding agent present in the composition being non-radiolabeled, and allowing the binding agent to form a binding agent/antigen pair, whereby an effective host ~~immune~~ T cell response is elicited against a second epitope on the antigen in the binding agent/antigen pair.

114-116. **(Cancelled)**

117. **(Currently amended)** The method of ~~Claim~~ claim 113, ~~wherein the host immune response comprises~~ further comprising a humoral immune response.

118. **(Currently amended)** The method of ~~Claim~~ claim 113, wherein the multi-epitopic *in vivo* antigen is a soluble antigen.

119. **(Currently amended)** The method of ~~Claim~~ claim 118, wherein the soluble antigen is a soluble tumor-associated antigen.

120. **(Currently amended)** The method of ~~Claim~~ claim 118, wherein the soluble antigen is associated with a human ~~disease or condition~~cancer.

121-122. **(Cancelled)**

123. **(Currently amended)** The method of ~~Claim~~ claim 113, wherein the binding agent is an antibody or a polypeptide including an antigen binding portion thereof.

124. **(Cancelled)**

125. **(Currently amended)** The method of ~~Claim~~ claim 123, wherein the antibody is B43.13 which is produceable by a hybridoma having ATCC deposit number PTA-1883.

126-128. **(Cancelled)**

129. **(Currently amended)** The method of ~~Claim~~ claim 113, wherein the antigen is CA125.

130. **(Currently amended)** The method of ~~Claim~~ claim 129, wherein the level of CA125 in the host's serum is greater than 100U/ml.

131. **(Currently amended)** The method of ~~Claim~~ claim 123, wherein the antigen is a soluble circulating antigen and the antigen is contacted with a sufficient amount of antibody to present all the circulating antigen to the immune system.

132. **(Currently amended)** The method of ~~Claim~~ claim 113, wherein the antigen is contacted with binding agent in an amount of from 0.1 μg to 2 mg per kg of body weight of the host.

133. **(Currently amended)** The method of ~~Claim~~ claim 132, wherein the antigen is contacted with binding agent in an amount from 1 μg to 200 μg per kg of body weight of the host.

134. **(Currently amended)** The method of ~~Claim~~ claim 133, wherein allowing the binding agent to form a binding agent/antigen pair presents other epitopes on the antigen to the host's immune system.

135. **(Currently amended)** A method for inducing a therapeutic host immune response against a multi-epitopic *in vivo* antigen that does not elicit an effective host immune response, comprising administering to the host a composition comprising a ~~non-radiolabeled~~ binding agent that specifically binds to an epitope on the antigen, the binding agent present in the composition being non-radiolabeled, thereby forming a binding agent/antigen pair, whereby an effective ~~immune~~ host T cell response is elicited against a second epitope of the antigen, the binding agent

being present in the composition in an amount of from 0.1 μg to 2 mg per kg of body weight of the host.

136. **(Cancelled)**

137. **(Currently amended)** The method of ~~Claim~~ claim 135, wherein the antigen is a soluble antigen.

138. **(Currently amended)** The method of ~~Claim~~ claim 135, wherein the antigen is a tumor antigen.

139. **(Currently amended)** The method of ~~Claim~~ claim 137, wherein the antigen is a tumor antigen.

140. **(Cancelled)**

141. **(Currently amended)** The method of ~~Claim~~ claim 113, wherein the composition comprising a binding agent further comprises one or more adjuvants, one or more carriers, one or more excipients, one or more stabilizers, one or more pharmaceutically acceptable carriers and/or physiologically acceptable saline.

142. **(Currently amended)** The method of ~~Claim~~ claim 113, wherein contacting comprises administering by any immunologically suitable route.

143. **(Currently amended)** The method of ~~Claim~~ claim 142, wherein administering by any immunologically suitable routes comprises intravenous, subcutaneous, intraperitoneal, intradermal, intramuscular, or intralymphatic routes.

144. **(Currently amended)** The method of ~~Claim~~ claim 142, wherein administering by any immunologically suitable route comprises administering in solution, tablet, or aerosol form.

145-169. **(Cancelled)**

170. (**Currently amended**) The method of ~~Claim~~ claim 135, wherein the composition comprising a binding agent further comprises one or more adjuvants, one or more carriers, one or more excipients, one or more stabilizers, one or more pharmaceutically acceptable carriers and/or physiologically acceptable saline.

171. (**Previously presented**) The method of claim 135, wherein the composition is administered by any immunologically suitable route.

172. (**Currently amended**) The method of ~~Claim~~ claim 171, wherein administering by any immunologically suitable route comprises intravenous, subcutaneous, intraperitoneal, intradermal, intramuscular, or intralymphatic routes.

173. (**Currently amended**) The method of ~~Claim~~ claim 171, wherein administering by any immunologically suitable route comprises administering in solution, tablet, or aerosol form.

174. (**Currently amended**) A method for inducing a therapeutic host immune response against a multi-epitopic *in vivo* antigen that does not elicit an effective host immune response, the method comprising contacting a multi-epitopic *in vivo* antigen present in a host's serum with a composition comprising a binding agent that specifically binds to an epitope on the antigen, the binding agent present in the composition being non-radiolabeled, and allowing the binding agent to form a binding agent/antigen complex, wherein the binding agent/antigen complex elicits an effective host ~~immune~~ T cell response against a second epitope of the multi-epitopic *in vivo* antigen.

175. (**Currently amended**) The method of ~~Claim~~ claim 174, wherein the effective host immune response is elicited against an epitope on the binding agent/antigen complex.

176-179. **Cancelled**)

180. (**Currently amended**) The method of ~~Claim~~ claim 174, wherein the multi-epitopic *in vivo* antigen is a soluble antigen.

181. (**Currently amended**) The method of claim 180, wherein the soluble antigen is a soluble tumor-associated antigen.

182. (**Currently amended**) The method of ~~Claim~~ claim 180, wherein the soluble antigen is associate with a human ~~disease or condition~~cancer.

183-184. (**Cancelled**)

185. (**Currently amended**) The method of ~~Claim~~ claim 174, wherein the binding agent is an antibody or a polypeptide including an antigen binding portion thereof.

186. (**Cancelled**)

187. (**Currently amended**) The method of ~~Claim~~ claim 174, wherein the binding agent is B43.13 which is produceable by a hybridoma having ATCC deposit number PTA-1883.

188-189. (**Cancelled**)

190. (**Currently amended**) The method of ~~Claim~~ claim 185, wherein the antibody ~~comprises a native~~ is a non-human antibody.

191. (**Currently amended**) The method of ~~Claim~~ claim 174, wherein the antigen is CA125.

192. (**Currently amended**) The method of ~~Claim~~ claim 191, wherein the level of CA125 in the host's serum is greater than 100 U/ml.

193. (**Currently amended**) The method of ~~Claim~~ claim 185, wherein the antigen is soluble circulating antigen and the antigen is contacted with a sufficient amount of antibody to present all the circulating antigen to the immune system.

194. (**Currently amended**) The method of ~~Claim~~ claim 174, wherein the antigen is contacted with binding agent in an amount from 0.1 μg to 2 mg per kg of body weight of the host.

195. (**Currently amended**) The method of ~~Claim~~ claim 194, wherein the antigen is contacted with binding agent in an amount from 1 μg to 200 μg per kg of body weight of the host.

196. (**Currently amended**) The method of ~~Claim~~ claim 174, wherein allowing the binding agent to form a binding agent/antigen complex presents other epitopes on the antigen to the host's immune system.

197. (**Currently amended**) The method of ~~Claim~~ claim 174, wherein the composition comprising a binding agent further comprises one or more adjuvants, one or more carriers, one or more excipients, one or more stabilizers, one or more pharmaceutically acceptable carriers and/or physiologically acceptable saline.

198. (**Currently amended**) The method of ~~Claim~~ claim 174, wherein contacting comprises administering by any immunologically suitable route.

199. (**Currently amended**) The method of ~~Claim~~ claim 198, wherein administering by any immunologically suitable route comprises intravenous, subcutaneous, intraperitoneal, intradermal, intramuscular, or intralymphatic routes.

200. (**Currently amended**) The method of ~~Claim~~ claim 198, wherein administering by any immunologically suitable route comprises administering in solution, tablet, or aerosol form.

201. (**Currently amended**) A method for inducing a therapeutic host immune response against a multi-epitopic *in vivo* antigen that does not elicit an effective host immune response, comprising administering to the host a composition comprising a ~~non-radiolabeled~~ binding agent that specifically binds to an epitope on the antigen, the binding agent present in the composition being non-radiolabeled, thereby forming a binding agent/antigen complex, whereby an effective ~~immune~~ host T cell response is elicited against the binding agent/antigen complex, the binding agent being present in the composition in an amount of from 0.1 μg to 2 mg per kg of body weight of the host.

202. (**Currently amended**) The method of ~~Claim~~ claim 201, wherein the antigen is a soluble antigen.

203. (**Currently amended**) The method of ~~Claim~~ claim 201, wherein the antigen is a tumor antigen.

204. (**Currently amended**) The method of ~~Claim~~ claim 202, wherein the antigen is a tumor antigen.

205. (**Cancelled**)

206. (**Currently amended**) The method of ~~Claim~~ claim 201, wherein the composition comprising a binding agent further comprises one or more adjuvants, one or more carriers, one or more excipients, one or more stabilizers, one or more pharmaceutically acceptable carriers and/or physiologically acceptable saline.

207. (**Previously presented**) The method of claim 201, wherein the composition is administered by any immunologically suitable route.

208. (**Currently amended**) The method of ~~Claim~~ claim 207, wherein administering by any immunologically suitable route comprises intravenous, subcutaneous, intraperitoneal, intradermal, intramuscular, or intralymphatic routes.

209. (**Currently amended**) The method of ~~Claim~~ claim 207, wherein administering by any immunologically suitable route comprises administering in solution, tablet, or aerosol form.

210-234. (**Cancelled**)

235. (**Previously presented**) The method according to any one of claims [[115-121]]117-120, 129, 130, 132-135, 137-139, 141-144, 170-175, [[177-183]]180, 182, 191-192, 194-204, or 206-209 wherein the binding agent is an antibody.

236. (**Previously presented**) The method of claim 235, wherein the antibody is a murine monoclonal antibody.

237. (**Previously presented**) The method of claim 235, wherein the antibody is an Ab1 antibody.

238. (**Previously presented**) The method according to any one of claims 123, 185, 190, or 193, wherein the antibody is an Ab1 antibody.

239. (**Previously presented**) The method according to claim 123 or 185 wherein the antibody or polypeptide including an antigen binding portion thereof is selected from the group consisting of a chimeric monoclonal antibody, a genetically engineered monoclonal antibody, a Fab fragment, a $F(ab')_2$ fragment, and a single chain fragment.

240. (**New**) The method according to claim 113, wherein the binding agent is administered to a host by any immunologically suitable route.

241. (**New**) The method according to claim 113, wherein the T cell response is directed against a host cell of the patient.

242. (**New**) The method according to claim 241, wherein the host cell of the patient is a cancerous cell.

243. (**New**) The method according to claim 113, wherein the antigen is a cell-surface-associated antigen with a carbohydrate moiety.

244. (**New**) The method according to claim 243, wherein the cell-surface associated antigen is a tumor-associated antigen.

245. (**New**) The method of claim 240, wherein administering by any immunologically suitable routes comprises intravenous, subcutaneous, intraperitoneal, intradermal, intramuscular, or intralymphatic routes.

246. (**New**) The method of claim 240, wherein administering by any immunologically suitable route comprises administering in solution, tablet, or aerosol form.

247. (**New**) The method according to claim 113, wherein the binding agent is photoactivated.

248. (**New**) The method according to claim 135, wherein the binding agent is photoactivated.

249. (**New**) The method according to claim 174, wherein the binding agent is photoactivated.

250. (**New**) The method according to claim 201, wherein the binding agent is photoactivated.

251. (**New**) The method of claim 135, further comprising a humoral immune response.

252. (**New**) The method of claim 174, further comprising a humoral immune response.

253. (**New**) The method of claim 201, further comprising a humoral immune response.

254. (**New**) The method of claim 113, wherein the binding agent is administered in a 2 mg dosage.

255. (**New**) The method of claim 135, wherein the binding agent is administered in a 2 mg dosage.

256. (**New**) The method of claim 174, wherein the binding agent is administered in a 2 mg dosage.

257. (**New**) The method of claim 201, wherein the binding agent is administered in a 2 mg dosage.